Nurix Therapeutics Ownership | Who Owns Nurix Therapeutics?

Overview Forecast RevenueFinancials Chart

Nurix Therapeutics Ownership Summary

Nurix Therapeutics is owned by 15.95% institutional investors, 1.13% insiders, and 82.93% retail investors. Blackrock is the largest institutional shareholder, holding 12.42% of NRIX shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 3.13% of its assets in Nurix Therapeutics shares.

NRIX Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Nurix Therapeutics	15.95%	1.13%	82.93%
Sector	Healthcare Stocks	232.86%	10.65%	-143.51%
Industry	Biotech Stocks	382.13%	10.41%	-292.54%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Blackrock	6.82M	12.42%	$142.33M
Fmr	8.89M	10.56%	$82.12M
Blackrock funding, inc. /de	8.88M	9.33%	$168.36M
Deep track capital, lp	6.06M	7.20%	$55.97M
Vanguard group	5.95M	6.26%	$112.86M
Morgan stanley	4.88M	5.63%	$92.59M
Baker bros. advisors lp	3.88M	4.61%	$35.87M
Commodore capital lp	3.78M	4.49%	$34.93M
Redmile group	3.68M	4.37%	$33.99M
Vestal point capital, lp	3.48M	4.13%	$32.11M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Redmile group	3.68M	3.31%	$33.99M
Commodore capital lp	3.78M	1.71%	$34.93M
Deep track capital, lp	6.06M	1.56%	$55.97M
Kynam capital management, lp	2.17M	1.49%	$20.04M
Vestal point capital, lp	3.48M	1.45%	$32.11M
Rhenman & partners asset management ab	537.50K	0.95%	$10.20M
Soleus capital management	1.22M	0.85%	$23.13M
Affinity asset advisors	967.62K	0.78%	$8.94M
Westhill financial advisors	228.33K	0.68%	$3.54M
Rubric capital management lp	2.47M	0.56%	$46.93M

Top Buyers

Holder	Shares	% Assets	Change
Morgan stanley	4.88M	0.01%	2.62M
Rubric capital management lp	2.47M	0.56%	2.47M
Blackrock	6.82M	0.00%	2.24M
Blackrock funding, inc. /de	8.88M	0.00%	2.11M
Vestal point capital, lp	3.48M	1.45%	1.48M

Top Sellers

Holder	Shares	% Assets	Change
Price t rowe associates inc /md/	1.10M	0.00%	-1.93M
Fmr	8.89M	0.00%	-1.55M
Ra capital management	-	-	-1.33M
T. rowe price investment management	1.20M	0.01%	-1.28M
Wellington management group llp	255.79K	0.00%	-1.21M

New Positions

Holder	Shares	% Assets	Change	Value
Rubric capital management lp	2.47M	0.56%	2.47M	$46.93M
Vanguard fiduciary trust	632.23K	0.00%	632.23K	$9.80M
Fisher asset management	384.83K	0.00%	384.83K	$5.96M
Norges bank	318.80K	0.00%	318.80K	$6.01M
Lighthouse investment partners	50.00K	0.01%	50.00K	$462.00K

Sold Out

Holder	Change
True wealth design	-4.00
Ifp advisors	-6.00
Nelson, van denburg & campbell wealth management group	-9.00
Federated hermes	-15.00
Amundi	-17.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Dec 31, 2025	39	-77.59%	15,163,987	-82.11%	15	0.16%	26	-68.67%	7	-88.14%
Sep 30, 2025	46	-72.12%	9,091,319	-89.71%	10	0.10%	18	-80.43%	17	-59.52%
Jun 30, 2025	164	-4.09%	88,304,128	5.07%	105	1.04%	91	-3.19%	42	-17.65%
Mar 31, 2025	171	-3.93%	84,588,676	4.29%	101	0.69%	93	-11.43%	51	10.87%
Dec 31, 2024	177	1.72%	81,111,271	20.04%	120	1.40%	103	9.57%	47	-16.07%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Vanguard Total Stock Mkt Idx Inv	3.23M	3.13%	30.63K
State Street® SPDR® S&P® Biotech ETF	3.13M	3.03%	-30.98K
Vanguard US Total Market Shares ETF	2.13M	2.79%	196.50K
iShares Russell 2000 ETF	2.38M	2.30%	20.07K
Fidelity Select Health Care	1.69M	2.21%	90.00K
Xtrackers MSCI World Swap ETF 1C	2.14M	2.08%	-13.47K
US Small-Cap Growth II Equity Comp	1.35M	1.76%	14.21K
Pictet-Biotech P USD	1.78M	1.72%	1.78M
ARK Genomic Revolution ETF	1.72M	1.67%	72.94K
ARK Genomic Revolution	1.63M	1.57%	96.44K

Recent Insider Transactions

Date	Name	Role	Activity	Value
May 05, 2026	van Houte Hans	Chief Financial Officer	Sell	$223.32K
May 05, 2026	van Houte Hans	Chief Financial Officer	Sell	$10.00K
May 04, 2026	Ring Christine	Chief Legal Officer	Sell	$138.21K
May 01, 2026	Ring Christine	Chief Legal Officer	Sell	$90.41K
Apr 30, 2026	van Houte Hans	Chief Financial Officer	Sell	$39.75K

Insider Transactions Trends

Date	Buy	Sell
2026 Q2	-	8
2026 Q1	-	9
2025 Q4	-	7
2025 Q3	-	4
2025 Q2	-	4

NRIX Ownership FAQ

Who Owns Nurix Therapeutics?

Nurix Therapeutics shareholders are primarily institutional investors at 15.95%, followed by 1.13% insiders and 82.92% retail investors. The average institutional ownership in Nurix Therapeutics's industry, Biotech Stocks , is 382.13%, which Nurix Therapeutics falls below.

Who owns the most shares of Nurix Therapeutics?

Nurix Therapeutics’s largest shareholders are Blackrock (6.82M shares, 12.42%), Fmr (8.89M shares, 10.56%), and Blackrock funding, inc. /de (8.88M shares, 9.33%). Together, they hold 32.32% of Nurix Therapeutics’s total shares outstanding.

Does Blackrock own Nurix Therapeutics?

Yes, BlackRock owns 12.42% of Nurix Therapeutics, totaling 6.82M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 142.33M$. In the last quarter, BlackRock increased its holdings by 2.24M shares, a 48.90% change.

Who is Nurix Therapeutics’s biggest shareholder by percentage of total assets invested?

Redmile group is Nurix Therapeutics’s biggest shareholder by percentage of total assets invested, with 3.31% of its assets in 3.68M Nurix Therapeutics shares, valued at 33.99M$.

Who is the top mutual fund holder of Nurix Therapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Nurix Therapeutics shares, with 3.13% of its total shares outstanding invested in 3.23M Nurix Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools